TD Cowen Maintains Buy on Helus Pharma, Raises Price Target to $62

Benzinga Newsdesk www.benzinga.com Positive 88.1%

Neg 0% Neu 0% Pos 88.1%

TD Cowen analyst Ritu Baral maintains Helus Pharma (NASDAQ:HELP) with a Buy and raises the price target from $8 to $62.

Comments

No comments yet. Be the first!